This supports suggestions that lowering GSH levels in COVID-19 patients may promote the development of infection, as with other viral diseases, while increasing GSH levels inhibited disease progression [46], and that viral infections generally induce the levels of glutathione and thioredoxin, as well as of the peroxiredoxin (PRDX) family [47]. The gene discussed is TXN; the disease is COVID-19.